Drug companies join NIH in study of Alzheimer’s and other diseases
Under a five-year collaboration, 10 drug companies and the National Institutes of Health (NIH) have agreed to share scientists, tissue and blood samples, and data. The Accelerating Medicines Project (AMP) aims to decipher the biology behind Alzheimer’s disease, Type 2 diabetes, rheumatoid arthritis and lupus, and to identify targets for new drugs. The Alzheimer’s Association is involved in AMP as a steering committee member.
http://www.optimumseniorcare.com/services/alzheimerscare.php